

Apolizumab Biosimilar - Research Grade

Product Code: ICH5352

More Information

Species Reactivity: Human

Target: HLA-DRB

Concentration: 5mg/ml

Isotype: IgG1 - kappa

Host: CHO Cells

product name H2: Apolizumab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P79483;Q30154;P01911

Shipping Conditions: Blue ice

background: HLA-DR beta (HLA-DRB) is a class II major histocompatibility molecule that presents antigen to CD4 T cells and is studied in immunology and B-cell malignancy. Offered as an unconjugated, non-therapeutic analog of apolizumab, this research-grade anti-human HLA-DRB recombinant monoclonal antibody is intended for research use only (RUO). It is manufactured to in vivo quality standards, formulated for low endotoxin, and supplied in scalable milligram (mg) to gram (g) quantities for high-throughput and heavy-usage laboratories. Typical uses include antigen-presentation and binding assays, in vitro functional screening, and in vivo immunology models requiring a reproducible reagent.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE



Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks